DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
MRK logo

Merck KGaA Stock Price

XTRA:MRK Community·€57.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 87 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

MRK Share Price Performance

€131.45
24.70 (23.14%)
​
€153.50
Fair Value
€131.45
24.70 (23.14%)
14.4% undervalued intrinsic discount
€153.50
Fair Value
Price €131.45
AnalystConsensusTarget €153.50
AnalystLowTarget €129.00
AnalystHighTarget €176.55
Thu, 3 Sep 26
Fair Value€153.50
Share Pricen/a

MRK Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €153.5 14.4% undervalued intrinsic discount

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

0users have liked this narrative
0users have commented on this narrative
54users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €129 1.9% overvalued intrinsic discount

Legacy Pharmaceutical And Chemical Businesses Will Decline As Regulations Tighten

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €176.55 25.5% undervalued intrinsic discount

Aging Populations And Digitalization Will Unlock Life Sciences Potential

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
MRK logo
Merck KGaA
14.4% undervalued intrinsic discount

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Sep
Read Narrative
MRK logo
Merck KGaA
1.9% overvalued intrinsic discount

Legacy Pharmaceutical And Chemical Businesses Will Decline As Regulations Tighten

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 17 Aug
Read Narrative
MRK logo
Merck KGaA
25.5% undervalued intrinsic discount

Aging Populations And Digitalization Will Unlock Life Sciences Potential

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 6 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
MRK logo

MRK: Electronics Upswing And Bio Techne Deal Will Shape Measured Outlook

Fair Value: €153.5 14.4% undervalued intrinsic discount
54 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
MRK logo

MRK: Rich Bio Techne Deal And New Guidance Will Shape Future Returns

Fair Value: €129 1.9% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
MRK logo

MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside

Fair Value: €176.55 25.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet established dividend payer.

0 Risks
3 Rewards
View Full Analysis

Merck KGaA Key Details

€21.1b

Revenue

€8.6b

Cost of Revenue

€12.5b

Gross Profit

€10.1b

Other Expenses

€2.4b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 12, 2026
5.45
59.09%
11.21%
38.5%
View Full Analysis

About MRK

Founded
1668
Employees
62136
CEO
Kai Beckmann
WebsiteView website
www.emdgroup.com

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Recent MRK News & Updates

User avatar
Narrative Update • Sep 03

MRK: Electronics Upswing And Bio Techne Deal Will Shape Measured Outlook

Analysts lifted the Merck KGaA fair value estimate by about €7 to €153.50 as they factored in slightly higher projected revenue growth and profit margins, with recent research pointing to improving momentum in the electronics unit and mixed views on valuation following the Bio Techne deal. Analyst Commentary Recent research on Merck KGaA shows a split view on the stock, with some analysts highlighting improving growth prospects and others more focused on valuation and deal risks.
User avatar
Narrative Update • Aug 17

MRK: Rich Bio Techne Deal And New Guidance Will Shape Future Returns

Merck KGaA’s analyst fair value has been updated from €121.00 to €129.00 as analysts factor in a higher blended set of price targets, including recent upward moves on the Street, alongside more cautious views on the Bio-Techne acquisition economics and a slightly higher discount rate. Analyst Commentary Recent Street research on Merck KGaA points to a mixed picture, with some updates tied closely to the agreed acquisition of Bio-Techne and shifting views on valuation and risk.

Recent updates

No updates

Merck KGaA Competitors

BAYN logo

Bayer

Symbol: XTRA:BAYN
Market cap: €47.3b
1SXP logo

SCHOTT Pharma KGaA

Symbol: XTRA:1SXP
Market cap: €3.5b
DMP logo

Dermapharm Holding

Symbol: XTRA:DMP
Market cap: €1.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide